: AbbVie shares jump as results beat expectations despite blockbuster Humira’s declining sales

Newer immunology drugs Skyrizi and Rinvoq boost sales in second quarter.

Previous post : Tupperware’s market cap almost triples as stock continues to skyrocket
Next post Futures Movers: U.S. oil prices touch highs above $80 a barrel for the first time in 3 months